Skip to main content
Erschienen in: Herz 2/2013

01.03.2013 | e-Herz: Original article

Elevated serum YKL-40 level predicts myocardial reperfusion and in-hospital MACE in patients with STEMI

verfasst von: M. Çetin, Dr. S.A. Kocaman, A. Çanga, A. Kırbaş, A. Yılmaz, T. Erdoğan, Ö Akgül, Y. Uğurlu, M.E. Durakoğlugil

Erschienen in: Herz | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Macrophages in atherosclerotic plaques secrete YKL-40, a new biomarker of acute and chronic inflammation in patients with stable CAD. We hypothesized that YKL-40 may be a specific marker reflecting the burden of localized inflammation in myocardium and a predictor in patients with STEMI. In this study, we investigated the relationship of YKL-40 to in-hospital major adverse cardiac events (MACE), reperfusion parameters and its predictors in patients with STEMI.

Methods

In total, 80 patients with STEMI and no history of prior coronary artery disease (CAD), who underwent primary percutaneous coronary intervention (p-PCI), were enrolled consecutively. In addition, 30 patients with normal coronary arteries (NCA) were enrolled as a control group. Cardiac biomarker levels including creatinine kinase-MB fraction (CK-MB), troponin-I, admission glucose and inflammatory markers including leukocytes and YKL-40 levels were measured as admission values.

Results

In our study, YKL-40 levels correlated to high-sensitivity CRP levels (r = 0.333, p = 0.003), TIMI risk score (r = 0.445, p < 0.001), age (r = 0.477, p < 0.001), pain to balloon time (r = 0.432, p < 0.001), leukocyte and neutrophil count (r = 0.386, p < 0.001 and r = 0.430, p < 0.001, respectively), hemoglobin (r = − 0.345, p = 0.002), admission and fasting blood glucose (r = 0.388, p < 0.001 and r = 0.427, p < 0.001), creatinine levels (r = 0.395, p < 0.001) and myocardial blush grade (r = − 0.334, p = 0.004). When the patients were divided into two groups determined by presence or absence of MACE, the patients with MACE had significantly higher levels of YKL-40 in comparison to the patients without MACE and the control group (194 ± 104, 114 ± 61 and 110 ± 53 μg/L, p < 0.001, respectively). In multivariate logistic regression analysis in STEMI patients, only YKL-40 level (OR: 1.011, 95%CI: 1.002–1.019, p = 0.011) and leukocyte count (OR: 1.264, 95%CI: 1.037–1.540, p = 0.020) were the independent predictors for MACE. Sensitivity and specificity of YKL-40 to predict MACE, when 125 μg/l was accepted as a cut-off value, were 84% and 70%, respectively.

Conclusion

We found that serum YKL-40 is related to older age, increased admission glucose levels, leukocyte counts and decreased hemoglobin levels; YKL-40 level and leukocyte count independently predicted MACE.
Literatur
1.
Zurück zum Zitat Liuzzo G, Biasucci LM, Gallimore JR et al (1994) The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 331:417–424PubMedCrossRef Liuzzo G, Biasucci LM, Gallimore JR et al (1994) The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 331:417–424PubMedCrossRef
2.
Zurück zum Zitat Toss H, Lindahl B, Siegbahn A, Wallentin L (1997) Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation 96:4204–4210PubMedCrossRef Toss H, Lindahl B, Siegbahn A, Wallentin L (1997) Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation 96:4204–4210PubMedCrossRef
3.
Zurück zum Zitat Hakala BE, White C, Recklies AD (1993) Human cartilage gp-39, a major secretory product protein family. J Biol Chem 268:25803–25810PubMed Hakala BE, White C, Recklies AD (1993) Human cartilage gp-39, a major secretory product protein family. J Biol Chem 268:25803–25810PubMed
4.
Zurück zum Zitat Rehli M, Krause SW, Andreesen R (1997) Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 43:221–225PubMedCrossRef Rehli M, Krause SW, Andreesen R (1997) Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 43:221–225PubMedCrossRef
5.
Zurück zum Zitat Johansen JS (2006) Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 53:172–209PubMed Johansen JS (2006) Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 53:172–209PubMed
6.
Zurück zum Zitat Rehli M, Krause SW, Andreesen R (1997) Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 43(2):221–225PubMedCrossRef Rehli M, Krause SW, Andreesen R (1997) Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 43(2):221–225PubMedCrossRef
7.
Zurück zum Zitat Johansen JS, Stoltenberg M, Hansen M et al (1999) Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology (Oxford) 38:618–626 Johansen JS, Stoltenberg M, Hansen M et al (1999) Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology (Oxford) 38:618–626
8.
Zurück zum Zitat Volck B, Price PA, Johansen JS et al (1998) YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians 110:351–360PubMed Volck B, Price PA, Johansen JS et al (1998) YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians 110:351–360PubMed
9.
Zurück zum Zitat Johansen JS, Olee T, Price PA et al (2001) Regulation of YKL-40 production by human articular chondrocytes. Arthritis Rheum 44:826–837PubMedCrossRef Johansen JS, Olee T, Price PA et al (2001) Regulation of YKL-40 production by human articular chondrocytes. Arthritis Rheum 44:826–837PubMedCrossRef
10.
Zurück zum Zitat Malinda KM, Ponce L, Kleinman HK et al (1999) Gp38 k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res 250:168–173PubMedCrossRef Malinda KM, Ponce L, Kleinman HK et al (1999) Gp38 k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res 250:168–173PubMedCrossRef
11.
Zurück zum Zitat Johansen JS, Jensen BV, Roslind A et al (2006) Serum YKL- 40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev 15:194–202PubMedCrossRef Johansen JS, Jensen BV, Roslind A et al (2006) Serum YKL- 40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev 15:194–202PubMedCrossRef
12.
Zurück zum Zitat Rehli M, Niller HH, Ammon C (2003) Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J Biol Chem 278:44058–44067PubMedCrossRef Rehli M, Niller HH, Ammon C (2003) Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J Biol Chem 278:44058–44067PubMedCrossRef
13.
Zurück zum Zitat Baeten D, Boots AM, Steenbakkers PG (2000) Human cartilage gp-39+, CD16+ monocytes in peripheral blood and synovium: correlation with joint destruction in rheumatoid arthritis. Arthritis Rheum 43:1233–1243PubMedCrossRef Baeten D, Boots AM, Steenbakkers PG (2000) Human cartilage gp-39+, CD16+ monocytes in peripheral blood and synovium: correlation with joint destruction in rheumatoid arthritis. Arthritis Rheum 43:1233–1243PubMedCrossRef
14.
Zurück zum Zitat Kirkpatrick RB, Matico RE, McNulty DE et al (1995) An abundantly secreted glycoprotein from Drosophila melanogaster is related to mammalian secretory proteins produced in rheumatoid tissues and by activated macrophages. Gene 153:147–154PubMedCrossRef Kirkpatrick RB, Matico RE, McNulty DE et al (1995) An abundantly secreted glycoprotein from Drosophila melanogaster is related to mammalian secretory proteins produced in rheumatoid tissues and by activated macrophages. Gene 153:147–154PubMedCrossRef
15.
Zurück zum Zitat Krause SW, Rehli M, Kreutz M et al (1996) Differential screening identifies genetic markers of monocyte to macrophage maturation. J Leukoc Biol 60:540–545PubMed Krause SW, Rehli M, Kreutz M et al (1996) Differential screening identifies genetic markers of monocyte to macrophage maturation. J Leukoc Biol 60:540–545PubMed
16.
Zurück zum Zitat Olga B, Yasuchika T, Tatsuro K et al (2010) Serum YKL-40 predicts adverse clinical outcomes in patients with chronic heart failure. J Card Fail 16(11):873–879 doi:10.1016/j.cardfail.2010.05.029CrossRef Olga B, Yasuchika T, Tatsuro K et al (2010) Serum YKL-40 predicts adverse clinical outcomes in patients with chronic heart failure. J Card Fail 16(11):873–879 doi:10.1016/j.cardfail.2010.05.029CrossRef
17.
Zurück zum Zitat Kucura M, Isman FK, Karadag B et al (2007) Serum YKL-40 levels in patients with coronary artery disease. Coron Artery Dis 18:391–396CrossRef Kucura M, Isman FK, Karadag B et al (2007) Serum YKL-40 levels in patients with coronary artery disease. Coron Artery Dis 18:391–396CrossRef
18.
Zurück zum Zitat Kastrup J, Johansen JS, Winkel P et al (2009) CLARICOR Trial Group. High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur Heart J 30(9):1066–1072PubMedCrossRef Kastrup J, Johansen JS, Winkel P et al (2009) CLARICOR Trial Group. High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur Heart J 30(9):1066–1072PubMedCrossRef
19.
Zurück zum Zitat Yasuda T, Kaneto H, Katakami N et al (2010) YKL-40, a new biomarker of endothelial dysfunction, is independently associated with albuminuria in type 2 diabetic patients. Diabetes Res Clin Pract doi:10.1016/j.diabres.2010.11.015 Yasuda T, Kaneto H, Katakami N et al (2010) YKL-40, a new biomarker of endothelial dysfunction, is independently associated with albuminuria in type 2 diabetic patients. Diabetes Res Clin Pract doi:10.1016/j.diabres.2010.11.015
20.
Zurück zum Zitat Kjaergaard AD, Bojesen SE, Johansen JS, Nordestgaard BG (2010) Elevated plasma YKL-40 levels and ischemic stroke in the general population. Ann Neurol 68(5):672–680PubMedCrossRef Kjaergaard AD, Bojesen SE, Johansen JS, Nordestgaard BG (2010) Elevated plasma YKL-40 levels and ischemic stroke in the general population. Ann Neurol 68(5):672–680PubMedCrossRef
21.
Zurück zum Zitat Henningsen KM, Therkelsen SK, Johansen JS et al (2000) Plasma YKL-40, a new biomarker for atrial fibrillation? Europace 11(8):1032–1036CrossRef Henningsen KM, Therkelsen SK, Johansen JS et al (2000) Plasma YKL-40, a new biomarker for atrial fibrillation? Europace 11(8):1032–1036CrossRef
22.
Zurück zum Zitat Killip T III, Kimball JT (1967) Treatment of myocardial infarction in a coronary care unit: a two year experience with 250 patients. Am J Cardiol 20:457–464PubMedCrossRef Killip T III, Kimball JT (1967) Treatment of myocardial infarction in a coronary care unit: a two year experience with 250 patients. Am J Cardiol 20:457–464PubMedCrossRef
23.
Zurück zum Zitat Morrow DA, Antman EM, Giugliano RP et al (2001) A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. Lancet 358:1571–1575PubMedCrossRef Morrow DA, Antman EM, Giugliano RP et al (2001) A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. Lancet 358:1571–1575PubMedCrossRef
24.
Zurück zum Zitat Morrow DA, Antman EM, Charlesworth A et al (2000) TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 102:2031–2037PubMedCrossRef Morrow DA, Antman EM, Charlesworth A et al (2000) TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 102:2031–2037PubMedCrossRef
25.
Zurück zum Zitat Thygesen K, Alpert JS, White HD (2007) Joint ESC/ACCF/AHA/WHF task force for the redefinition of myocardial infarction. Universal definition of myocardial infarction. Circulation 116:2634–2653PubMedCrossRef Thygesen K, Alpert JS, White HD (2007) Joint ESC/ACCF/AHA/WHF task force for the redefinition of myocardial infarction. Universal definition of myocardial infarction. Circulation 116:2634–2653PubMedCrossRef
26.
Zurück zum Zitat Alpert JS, Thygesen K, Antman E, Bassand JP (2000) Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 36:959–969PubMedCrossRef Alpert JS, Thygesen K, Antman E, Bassand JP (2000) Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 36:959–969PubMedCrossRef
27.
Zurück zum Zitat Schroder R (2004) Prognostic impact of early ST-segment resolution in acute ST-elevation myocardial infarction. Circulation 110:e506–510PubMedCrossRef Schroder R (2004) Prognostic impact of early ST-segment resolution in acute ST-elevation myocardial infarction. Circulation 110:e506–510PubMedCrossRef
28.
Zurück zum Zitat Antman EM, Hand M, Armstrong PW et al (2008) 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. Circulation 117:296–329PubMedCrossRef Antman EM, Hand M, Armstrong PW et al (2008) 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. Circulation 117:296–329PubMedCrossRef
29.
Zurück zum Zitat Anderson JL, Karagounis LA, Becker LC et al (1993) TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 Study. Circulation 87:1829–1839PubMedCrossRef Anderson JL, Karagounis LA, Becker LC et al (1993) TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 Study. Circulation 87:1829–1839PubMedCrossRef
30.
Zurück zum Zitat Gibson CM, Cannon CP, Daley WL et al (1996) TIMI frame count: a quantitativemethod of assessing coronary artery flow. Circulation 93:879–888PubMedCrossRef Gibson CM, Cannon CP, Daley WL et al (1996) TIMI frame count: a quantitativemethod of assessing coronary artery flow. Circulation 93:879–888PubMedCrossRef
31.
Zurück zum Zitat Gibson CM, Cannon CP, Murphy SA et al (2000) Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 101:125–130PubMedCrossRef Gibson CM, Cannon CP, Murphy SA et al (2000) Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 101:125–130PubMedCrossRef
32.
Zurück zum Zitat Gibson CM, Karha J, Murphy SA et al (2003) Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol 42:7–16PubMedCrossRef Gibson CM, Karha J, Murphy SA et al (2003) Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol 42:7–16PubMedCrossRef
33.
Zurück zum Zitat Junker N, Johansen JS, Hansen LT et al (2005) Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells. Cancer Sci 96:183–190PubMedCrossRef Junker N, Johansen JS, Hansen LT et al (2005) Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells. Cancer Sci 96:183–190PubMedCrossRef
34.
Zurück zum Zitat Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685–1695PubMedCrossRef Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685–1695PubMedCrossRef
35.
Zurück zum Zitat Shackelton LM, Mann DM, Millis AJ (1995) Identification of a 38-kDa heparin- binding glycoprotein (gp38 k) in differentiating vascular smooth muscle cells as amember of a group of proteins associated with tissue remodeling. J Biol Chem 270:13076–13083PubMedCrossRef Shackelton LM, Mann DM, Millis AJ (1995) Identification of a 38-kDa heparin- binding glycoprotein (gp38 k) in differentiating vascular smooth muscle cells as amember of a group of proteins associated with tissue remodeling. J Biol Chem 270:13076–13083PubMedCrossRef
36.
Zurück zum Zitat Malinda KM, Ponce L, Kleinman HK et al (1999) Gp38 k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res 250:168–173PubMedCrossRef Malinda KM, Ponce L, Kleinman HK et al (1999) Gp38 k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res 250:168–173PubMedCrossRef
37.
Zurück zum Zitat Nishikaw KC, Millis AJ (2003) Gp38 k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp Cell Res 287:79–87CrossRef Nishikaw KC, Millis AJ (2003) Gp38 k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp Cell Res 287:79–87CrossRef
38.
Zurück zum Zitat Kastrup J, Johansen JS, Winkel P (2009) High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur Heart J 30:1066–1072PubMedCrossRef Kastrup J, Johansen JS, Winkel P (2009) High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur Heart J 30:1066–1072PubMedCrossRef
39.
Zurück zum Zitat Nojgaard C, Host NB, Christensen IJ (2008) Serum levels of YKL-40 increases in patients with acute myocardial infarction. Coron Artery Dis 19:257–263PubMedCrossRef Nojgaard C, Host NB, Christensen IJ (2008) Serum levels of YKL-40 increases in patients with acute myocardial infarction. Coron Artery Dis 19:257–263PubMedCrossRef
40.
Zurück zum Zitat Hedegaard A, Sejersten RR, Johansen JS et al (2010) Plasma YKL-40 and recovery of left ventricular function after acute myocardial infarction. Scand J Clin Lab Invest 70:80–86PubMedCrossRef Hedegaard A, Sejersten RR, Johansen JS et al (2010) Plasma YKL-40 and recovery of left ventricular function after acute myocardial infarction. Scand J Clin Lab Invest 70:80–86PubMedCrossRef
Metadaten
Titel
Elevated serum YKL-40 level predicts myocardial reperfusion and in-hospital MACE in patients with STEMI
verfasst von
M. Çetin
Dr. S.A. Kocaman
A. Çanga
A. Kırbaş
A. Yılmaz
T. Erdoğan
Ö Akgül
Y. Uğurlu
M.E. Durakoğlugil
Publikationsdatum
01.03.2013
Verlag
Urban and Vogel
Erschienen in
Herz / Ausgabe 2/2013
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI
https://doi.org/10.1007/s00059-012-3671-4

Weitere Artikel der Ausgabe 2/2013

Herz 2/2013 Zur Ausgabe

CME Zertifizierte Fortbildung

Kardiogener Schock

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Chronisches Koronarsyndrom: Gefahr von Hospitalisierung wegen Herzinsuffizienz

06.05.2024 Herzinsuffizienz Nachrichten

Obwohl ein rezidivierender Herzinfarkt bei chronischem Koronarsyndrom wahrscheinlich die Hauptsorge sowohl der Patienten als auch der Ärzte ist, sind andere Ereignisse womöglich gefährlicher. Laut einer französischen Studie stellt eine Hospitalisation wegen Herzinsuffizienz eine größere Gefahr dar.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.